Table 2. Characteristics of the... | American Society of Hematology

Table 2.

Characteristics of the mbIL21-NK-cell product

Patient	Viability, %	Viable CD32⁺ cells,	CD3⁺ cells,	CD3⁻CD(16,56)⁺cells,	CD19⁺ cells,	CD14⁺ cells,
Patient	Viability, %	APCs, %	T cells: %, ×10⁵/kg	NK cells, %	B cells, %	monocytes, %
1	97	0.1	0.02, 0.00002	98.31	Not detected	Not detected
2	98	0.35	0.35, 0.0035	98.01	Not detected	Not detected
3	96	0.5	0.01, 0.0001	99.38	Not detected	Not detected
4	97	0.1	0.01, 0.001	98.77	Not detected	Not detected
5	98	0.38	Not detected	96.73	Not detected	0.11
6	96	0.07	0.06, 0.006	98.95	Not detected	Not detected
7	97	0.15	Not detected	99.46	Not detected	0.05
8	98	0.1	0.04, 0.04	98.46	Not detected	Not detected
9	98	0.24	0.03, 0.03	99.81	Not detected	Not detected
10	96	0.31	0.02, 0.06	99.80	Not detected	Not detected
11	97	Not detected	0.01, 0.03	99.72	Not detected	Not detected
12	97	0.07	0.07, 0.7	98.98	Not detected	Not detected
13	93	0.33	0.03, 0.3	99.33	0.54	Not detected

Patient	Viability, %	Viable CD32⁺ cells,	CD3⁺ cells,	CD3⁻CD(16,56)⁺cells,	CD19⁺ cells,	CD14⁺ cells,
Patient	Viability, %	APCs, %	T cells: %, ×10⁵/kg	NK cells, %	B cells, %	monocytes, %
1	97	0.1	0.02, 0.00002	98.31	Not detected	Not detected
2	98	0.35	0.35, 0.0035	98.01	Not detected	Not detected
3	96	0.5	0.01, 0.0001	99.38	Not detected	Not detected
4	97	0.1	0.01, 0.001	98.77	Not detected	Not detected
5	98	0.38	Not detected	96.73	Not detected	0.11
6	96	0.07	0.06, 0.006	98.95	Not detected	Not detected
7	97	0.15	Not detected	99.46	Not detected	0.05
8	98	0.1	0.04, 0.04	98.46	Not detected	Not detected
9	98	0.24	0.03, 0.03	99.81	Not detected	Not detected
10	96	0.31	0.02, 0.06	99.80	Not detected	Not detected
11	97	Not detected	0.01, 0.03	99.72	Not detected	Not detected
12	97	0.07	0.07, 0.7	98.98	Not detected	Not detected
13	93	0.33	0.03, 0.3	99.33	0.54	Not detected